Swiss National Bank Boosts Holdings in Dianthus Therapeutics, Inc. $DNTH

Swiss National Bank grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 119.7% in the first quarter, HoldingsChannel reports. The fund owned 69,000 shares of the company’s stock after buying an additional 37,600 shares during the quarter. Swiss National Bank’s holdings in Dianthus Therapeutics were worth $5,790,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares during the last quarter. UBS Group AG raised its position in shares of Dianthus Therapeutics by 342.6% in the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after buying an additional 469,547 shares during the period. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics in the fourth quarter valued at $765,000. BNP Paribas Financial Markets boosted its holdings in Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after acquiring an additional 441,156 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Dianthus Therapeutics by 626.4% during the third quarter. JPMorgan Chase & Co. now owns 68,124 shares of the company’s stock valued at $2,681,000 after acquiring an additional 58,746 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on DNTH shares. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Wedbush lifted their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Insider Activity

In other news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the sale, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 87,779 shares of company stock worth $7,985,235. 3.02% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Trading Down 2.8%

Shares of Dianthus Therapeutics stock opened at $101.61 on Wednesday. Dianthus Therapeutics, Inc. has a twelve month low of $18.08 and a twelve month high of $107.99. The stock has a market cap of $5.56 billion, a price-to-earnings ratio of -24.60 and a beta of 1.20. The company has a fifty day moving average price of $91.46 and a 200 day moving average price of $77.15.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.